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Our study evaluated whether 1999 National Cancer Institute (NCI) chemoradiation guidelines for cervical cancer impacted
treatment of women ≥55 years. We identiﬁed 385 women ≥55 years (median, 72 years) diagnosed with stage II-IVA cervical
cancer between January, 1998 and December, 2002 in the United States Surveillance, Epidemiology, and End Results (SEER)-
Medicare registries. Chemoradiation frequency tables were constructed for age, race, community setting, socioeconomic status,
and comorbidity index. Of 385 women, 166 (43%) received chemoradiation as primary treatment. Prior to the 1999 NCI clinical
alert, 5/43 (12%) in 1998 and 24/54 (44%) in 1999 received chemoradiation. The chemoradiation proportion was 41% (36/87)
in 2000, 48% (51/107) in 2001, and 53% (50/94) in 2002 (trend, P<. 01). Women ≥71 years had signiﬁcantly lower odds of
chemoradiation(P = .04).WhileSEER-Medicaredataindicatedanincreasingtrendforchemoradiationafterthe1999NCIclinical
alert, chemoradiation was less frequent in elderly women with cervical cancer.
Copyright © 2008 Charles Kunos et al. This is an open access article distributed under the Creative Commons AttributionLicense,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
Cervical cancer is the second most frequently diagnosed
cancer among women worldwide, with nearly 80 percent
arising among women in developing countries [1]. Despite
eﬀective screening modalities, nearly 40 percent of women
in the United States present with locally advanced stage II-
IVA cervical cancers extending beyond the cervix to invade
vaginal or parametrial, pelvic sidewall, bladder, or rectal
tissues [1].
In women with locally advanced cervical cancer, three
randomized trials have shown concurrent pelvic radiation
and platinum-based chemotherapy meaningfully contribute
to improved disease-free survival [2–4]. These compelling
clinicalresultspromptedtheNationalCancerInstitute(NCI)
to issue a publicized national clinical alert in February,
1999advisingconcurrentplatinum-basedchemotherapyand
radiation for women with locally advanced cervical cancer
[5].
According to the United States Surveillance, Epidemi-
ology, and End-Results (SEER) cancer registries between
January, 1998 and December, 2002, 35 percent of annual
incident cervical cancer patients arose in women aged 55
years or older (≥5 5 ) .H o w e v e r ,w o m e n≥55 years accounted
for 55 percent of cervical cancer-related mortality during
this time period. Widening disparity between cervical cancer
incidence and mortality among women ≥55 years questions
whetherchemoradiationhasbeenimplementedasanational
practice pattern in this patient population. Population-
based studies are needed to evaluate the national impact
of the 1999 NCI clinical alert advising chemoradiation
for locally advanced cervical cancer. The merged SEER-
Medicare dataset oﬀers a population-based cohort of women
≥55 years longitudinally tracked over the course of cancer2 Journal of Oncology
diagnosis, treatment, and follow-up [6]. The utility of SEER-
Medicare data to identify chemotherapy administration has
been validated [7]. This study determines the frequency
of chemoradiation administration in women ≥55 years
diagnosed with cervical cancer immediately before and after
the 1999 NCI clinical alert using the population-based
SEER-Medicaredataset.Secondaryaimsincludedidentifying
factors in women aged ≥55 years associated with decreased
chemotherapy administration during radiation.
2. Methods
2.1. Data Source. Data were abstracted from the NCI-
sponsored SEER-Medicare program using the SEER 11-
registries plus Alaska 1998–2003 dataset (July, 2006 edition,
[8]). Because SEER data contain no unique personal iden-
tiﬁers and thus are available for public use and research,
approval by an ethics committee or informed consent is
not necessary to perform our analyses. In general, SEER
data cover 26 percent of the US population, and therefore,
are considered representative of the whole US population
[8]. The SEER program registries routinely collect data on
patient demographics (i.e., age, race [Caucasian, African-
American, Asian, Hispanic, or other], patient residence, and
socioeconomic status [income per census tract]), primary
tumor site (i.e., cervix), tumor morphology and stage at
diagnosis, ﬁrst course of treatment, and follow-up for vital
status. The SEER program does not record chemotherapy
administration.
To identify claims for chemotherapy administration [7],
datawereabstractedfromthreemergedSEER-Medicareﬁles:
Medicare provider analysis and review (MEDPAR), carrier
claims (NCH), and outpatient claims (OUTSAF). MEDPAR
ﬁles record all calendar year part A short stay, long stay, and
skilled nursing facility claims. NCH ﬁles contain calendar
year Center for Medicare and Medicaid Services (CMS)
physician/supplier part B claims. OUTSAF ﬁles list calendar
year claims for hospital outpatient departments, rural health
clinics, renal dialysis facilities, outpatient rehabilitation facil-
ities, comprehensive outpatient rehabilitation facilities, and
community mental health centers [9]. Procedure codes for
chemotherapy administration made within 3 months after
diagnosis of cervical cancer were ascertained [10].
2.2. Study Population. The study population consisted of all
female patients, without previous or synchronous invasive
cancers,whowerediagnosedwithstageII,III,orIVAcervical
cancer between 1998 and 2002 (n = 3,601). Stage I patients
(n = 1,363) were excluded because they are not reliably
substaged (i.e., IB1 or IB2) in the SEER-Medicare database
and the majority underwent deﬁnitive surgery (1,044 of
1,363 [76.6%]). Women with unknown stage (n = 357),
stage 0 (n = 4 7 ) ,a n ds t a g eI V B( n = 402) cervical
cancers were excluded. To ensure that chemotherapy claims
coincided with radiation and are not missed secondary
to payment by private insurance (n = 431), included
women must have had Medicare parts A and B coverage
for the duration of their cancer care (n = 1,001) [7]. For
determination of chemoradiation administration, included
women ≥55 years must have undergone radiation (external
pelvic and brachytherapy implant) for primary treatment of
their cervical cancer (n = 385).
2.3.ComorbidityIndex. TheCharlsoncomorbidityindexisa
summary measure of 19 comorbid conditions, each assigned
a weighting factor according to its potential for inﬂuencing
mortality [11]. Charlson comorbidity indices [11]w e r e
calculated by abstracting Medicare ICD-9-CM diagnosis and
procedure codes relating to cardiovascular, cerebrovascular,
hepatic, renal, diabetic, connective tissue, or neoplastic
diseaseamonginpatientandoutpatientclaimsmadeforeach
womanoneyearpriortothediagnosisofcervicalcancer[12–
14]. Women diagnosed with chronic end-stage renal disease
or listed in the SEER-Medicare dataset as having diagnosis
codes for renal disease, renal failure, or renal insuﬃciency
were considered women as having renal disease comorbidity
[10].
2.4. Statistical Analysis. For this analysis, the day of diag-
nosis in SEER was arbitrarily assigned as the 15th of the
m o n t h .W o m e nw e r ec o n s i d e r e dt oh a v er e c e i v e dc o n -
current chemoradiation therapy if there was at least one
submitted billing claim for chemotherapy within a three-
month period after diagnosis and radiation treatment. Chi-
square tests for categorical variables and Student’s t-tests
for continuous variables were used to compare diﬀerences
in demographic and tumor variables by chemoradiation
administration. Adjusted odds ratios for chemoradiation
were generated using multivariate logistic regression models
sequentially controlling age, race, residence, socioeconomic
status, comorbidity, tumor stage, and histology as deﬁned
in Table 1.AP-value α<0.05 (two-sided) was used
to determine statistical signiﬁcance. Computer programing
and statistical analyses were performed using SAS software
version 9.1 (SAS Institute, Cary, NC).
3. Results
3.1.PatientDemographics. Afterexclusions,385womenaged
≥55 years underwent pelvic radiation and intracavitary
brachytherapy for primary treatment of cervical cancer
between January, 1998 and December, 2002. Median age
was 72 years (range 55–94 years). Table 1 presents patient
demographic and tumor variables for the 385 women
included in this analysis. The majority of cases were stage
II squamous cell cancers diagnosed in Caucasian women
who had minimal comorbidities and who resided in large
metropolitan areas.
3.2. Concurrent Chemoradiation. Among women aged ≥55
years identiﬁed in the SEER-Medicare dataset, 166 of 385
(43%)receivedchemoradiation.Cisplatinchemotherapywas
speciﬁcally claimed in 129 of 166 (78%) women. Before the
1999 NCI clinical alert, 30 percent of women aged ≥55 years
(29 of 97 women) identiﬁed in the SEER-Medicare registry
received at least one chemotherapy dose during radiationJournal of Oncology 3
Table 1: Patient demographics (n = 385).
Age∗ 73.3 ±0.37 (55–94 years)
Stage
II 213 (55.3%)
III 163 (42.3%)
IVA 9 (2.3%)
Year of diagnosis
1998 43 (11.2%)
1999 54 (14.0%)
2000 87 (22.6%)
2001 107 (27.8%)
2002 94 (24.4%)
Histology
Squamous 289 (75.1%)
Adenocarcinoma 55 (14.3%)
Adenosquamous 13 (3.4%)
Other 28 (7.3%)
Race
Caucasian 237 (61.6%)
African-American 74 (19.2%)
Asian 34 (8.8%)
Hispanic 25 (6.5%)
Other 15 (3.9%)
Location
Big metropolitan (≥250,000) 235 (61.0%)
Metropolitan (20,000 to 249,999) 94 (24.4%)
Urban (2,500–19,999, adjacent
metropolitan area)
17 (4.4%)
Less urban (2,500–19,999, not
adjacent metro area)
32 (8.3%)
Rural (<2,500) 7 (1.8%)
Socioeconomic status (median
income per census tract)∗ $44,540 ±$1,125
Comorbidity index, Charlson
0 274 (71.2%)
1 63 (16.4%)
2 28 (7.3%)
3+ 20 (5.2%)
∗Mean ±Standard Error of Mean.
(see Table 2). In the year 2000 and after the 1999 NCI
clinical alert, the proportion receiving chemoradiation was
41 percent of women aged ≥55 years (36 of 87 women).
Afterwards, the proportion receiving chemoradiation was
greater than 50 percent (see Table 2). Between 1998 and
2002, a signiﬁcant increasing trend for chemoradiation
administration was observed among women aged ≥55 years
registered in the SEER-Medicare dataset (P<. 01). The
median number of chemotherapy claims during radiation
was four (mean 4.2, standard deviation 1.9, Table 2). Among
women treated with chemoradiation, 78 of 166 (47%)
received ﬁve or more cycles of chemotherapy. Table 3 com-
Table 2: Concurrent chemoradiation by year of treatment and by
number of claims (cycles) within ±3 months of radiation.
Year∗ # Chemoradiation/Total # Women
1998 5/43 (11.6%)
1999 24/54 (44.4%)
2000 36/87 (41.4%)
2001 51/107 (47.7%)
2002 50/94 (53.2%)
Cycles Total # Women
12 0
2t o4 6 8
5t o6 6 9
7o rm o r e 9
∗MH Chi-square = 15.83; P<. 001 for trend.
paresvariablesinunivariateanalysesevaluatingpatientswho
received concurrent chemotherapy and radiation compared
to those who received radiation alone. The mean age of
women receiving chemoradiation was signiﬁcantly younger
(Table 3, P<. 001). The proportion of women residing in
urban, less urban, and rural areas receiving chemoradiation
was signiﬁcantly higher than receiving radiation alone (20%
versus 10%, P = .03). Chemotherapy use during radiation
was not associated with race, socioeconomic status, tumor
histology or stage, or comorbidity index. The proportion of
womendiagnosedwithrenaldiseasecomorbiditywassimilar
among chemoradiation (18/166, 11%) and radiation alone
(21/219, 10%) treatment groups (P = .73).
Table 4 presents multivariate analyses for odds of receiv-
ing concurrent chemoradiation adjusting for patient demo-
graphicandtumordiﬀerences.Womenaged71yearsorolder
had a signiﬁcantly decreased odds of undergoing chemoradi-
ation treatment as compared to women aged 55 to 70 years
(P = .04). For women 71 years or older, the proportion
of women with renal disease who received chemoradiation
(9 of 95, 10%) and radiation alone (7 of 138, 5%) was
similar (P = .19). In multivariate analyses, women residing
in urban, less urban, and rural areas had signiﬁcantly
increased odds of undergoing chemoradiation treatment as
compared to women residing in metropolitan areas (P<
.001). The proportion of women 71 years or older in
big metropolitan, metropolitan, and urban/less urban/rural
areas was 42 percent (99 of 235), 35 percent (33 of 61), and
36 percent (20 of 56), respectively (P = .41). Race, socioe-
conomic status, comorbidity index, and tumor histology or
stage were not signiﬁcant confounders for chemoradiation
treatment.
4. Discussion
The present data from the US population-based SEER-
Medicare database indicate that the 1999 NCI clinical alert
for platinum-based chemoradiation has had an impact
on chemoradiation use for locally advanced stage II-IVA
cervical cancers diagnosed in women ≥55 years. Eighteen
months before the NCI clinical alert, less than 30 percent4 Journal of Oncology
Table 3: Univariate comparison of patients who received chemoradiation treatment versus those who received radiation treatment alone.
Chemoradiation (n = 166) RT alone (n = 219) P value∗
Age 71.7 ±0.48 74.4 ± 0.53 <.001
Stage .393
II 89 (53.6%) 124 (56.6%)
III 74 (44.6%) 89 (40.6%)
IVA 3 (1.8%) 6 (2.7%)
Histology .628
Squamous 129 (77.7%) 160 (73.1%)
Adenocarcinoma 23 (13.8%) 32 (14.6%)
Adenosquamous 4 (2.4%) 9 (4.1%)
Other 10 (6.0%) 18 (8.2%)
Race .445
Caucasian 97 (58.4%) 140 (63.9%)
African-American 34 (20.5%) 40 (18.3%)
Hispanic 6 (3.6%) 9 (4.1%)
Asian 14 (8.4%) 20 (9.1%)
Other 15 (9.0%) 10 (4.6%)
Location .028
Big metropolitan (≥250,000) 88 (53.0%) 147 (67.1%)
Metropolitan (20,000 to 249,999) 44 (26.5%) 50 (22.8%)
Urban (2,500–19,999, adjacent metro area) 11 (6.6%) 6 (2.7%)
Less urban (2,500–19,999, not adjacent metro area) 19 (11.4%) 13 (5.9%)
Rural (<2,500) 4 (2.4%) 3 (1.4%)
Socioeconomic status (median income per census tract) $44,308 ±$1,512 $44,715 ±$1,614 .858
Comorbidity index, Charlson .641
0 116 (69.9%) 158 (72.1%)
1 31 (18.7%) 32 (14.6%)
2 10 (6.0%) 18 (8.2%)
3+ 9 (5.4%) 11 (5.0%)
∗Student’s t-test or chi-square for frequency data.
of women ≥55 years received chemoradiation. However,
within 18 months of the NCI clinical alert, the proportion
of women ≥55 years with locally advanced cervical cancer
receiving chemoradiation signiﬁcantly rose to 50 percent.
Since chemoradiation use has steadily risen through the
last SEER-Medicare cohort available for study (i.e., 2002),
the recommendation has been followed but a substantial
fraction of women ≥55 years still did not receive concurrent
chemoradiation in 2002 three years after the NCI clinical
alert.
Age is a risk factor for pelvic and distant relapse as
well as death after treatment for cervical cancer. In mul-
tivariate analyses conducted by the Gynecologic Oncology
Group evaluating radiation and chemotherapeutic radiation
sensitizers [15], older patient age at diagnosis signiﬁcantly
conferred less cervical cancer recurrence or death. These
ﬁndings led to the controversial suggestion that younger
patient age at diagnosis was associated with high mortality;
and yet, the inferior mortality outcomes attributable to
younger patient age have vanished in the era of platinum-
based chemoradiation as no contemporary Gynecologic
Oncology Group or cooperative group study identiﬁes age
as a signiﬁcant confounder upon survival outcomes [2–
4]. While platinum-based chemoradiation appears to have
decreased mortality in younger women, it remains unknown
whether older women are deriving full survival beneﬁt from
chemoradiation treatment. Perceived and actual hematolog-
ical, renal, gastrointestinal, and neural toxicities of platinum
chemotherapy perhaps inﬂuence physicians to not consider
coadministration of chemotherapy during radiation in older
women. These data indicate that signiﬁcantly fewer women
olderthan71yearswhohavelocallyadvancedcervicalcancer
receive chemoradiation—even though the survival of these
older patients who receive chemoradiation approaches that
of younger patients who undergo chemoradiation treatment
[2–4, 16]. This study is not the ﬁrst to identify this age trend.
In a pattern of care study [17], it was reported that 63
percent of all women captured in this survey underwent con-
current chemotherapy and radiation in 1999, as compared to
26 percent in 1998. Twenty-ﬁve percent of women 60 years
or older received chemoradiation as compared to 48 percent
among women aged 40 years or less (P = .02) [17]. In an
earlier analysis of the SEER-Medicare database controlling
for racial and socioeconomic factors, increasing age wasJournal of Oncology 5
Table 4: Multivariate analysis for chemoradiation administration within 3 months after diagnosis in women with stages II-IVA cervical
cancer from 1998 to 2002.
Patient and tumor characteristics number of cases (n = 385) Odds ratio∗ of chemoradiation 95% Conﬁdence interval
Age
55–70 years 152 (39.5%) 1 —
>71 years 233 (60.5%) 0.62 0.42–0.94
Stage
II 213 (55.3%) 1 —
III 163 (42.3%) 0.96 0.63–1.47
IVA 9 (2.3%) 0.59 0.14–2.50
Histology
Squamous 289 (75.1%) 1 —
Adenocarcinoma 55 (14.3%) 0.84 0.45–1.57
Adenosquamous 13 (3.4%) 0.53 0.16–1.78
Other 28 (7.3%) 0.61 0.26–1.43
Race
Caucasian 237 (61.6%) 1 —
African-American 74 (19.2%) 1.22 0.72–2.06
Other 74 (19.2%) 1.28 0.75–2.18
Residence
Big Metropolitan area 235 (61.0%) 1 —
Metropolitan area 94 (24.4%) 1.48 0.89–2.45
Urban, less urban, rural 56 (14.5%) 2.63 1.41–4.91
Socioeconomic status, median income
<30,700 94 (24.4%) 1 —
30,701–39,425 93 (24.2%) 0.77 0.47–1.28
39,426–53,707 102 (26.5%) 0.72 0.43–1.20
>53,708 96 (24.9%) 1.18 0.70–1.98
Comorbidity index, Charlson
0 274 (71.2%) 1 —
1 63 (16.4%) 1.09 0.61–1.94
2 28 (7.3%) 0.72 0.31–1.65
3+ 20 (5.2%) 0.8 0.31–2.10
∗Adjusted for variables listed in the tables.
strongly associated (P<. 0001) with receiving neither
chemoradiation nor radiation treatment for cervical cancer
[18]. However, both studies capture only those women
treated through 1999, study periods ending when the 1999
NCI clinical alert were released. Thus, a true assessment of
the impact of the NCI clinical alert is essentially unknown.
The present data are the ﬁrst assessment of chemoradia-
tion treatment after the 1999 NCI clinical alert for chemora-
diation treatment of locally advanced cervical cancer in
women aged ≥55 years. The US SEER-Medicare dataset is an
NCI-sponsored cancer registry that reﬂects a wide range of
race/ethnic, demographic, and socioeconomic diversity and
that avails itself to cancer health service delivery analyses in
women aged ≥55 years. The data presented herein reﬂect
prospectively collected but not randomized practice and
usage of chemoradiation. These data measure the impact of
randomized clinical trials in cervical cancer, as popularized
by the national 1999 NCI clinical alert, on clinical chemora-
diation practices for the treatment of cervical cancer. Thus,
these data conveniently sample a small proportion of the
totalnumberofwomenwithlocallyadvancedcervicalcancer
treated in the US each year. Consequently, analyses on these
nonrandomly treated women can only be considered as an
interpretive guide for changing trends in chemoradiation
usage for locally advanced cervical cancer. Indeed, the
present data suggest that women ≥55 years with locally
advanced cervical cancer are increasingly likely to receive
chemoradiation. Data also suggest that chemoradiation use
has signiﬁcantly lagged behind in women 71 years or older
compared to women 55 to 70 years. Perhaps physicians
appliedtheNCIrecommendationstosomegroupsofwomen
more consistently than others.
In this study of the SEER-Medicare population, age
emerges as an important factor inﬂuencing whether patients
receive chemoradiation. While the NCI clinical alert has
strongly endorsed use of chemoradiation forall patients with
locally advanced cervical cancer, it is worth considering the
causes of disparity in chemoradiation use among younger6 Journal of Oncology
and older women. The exact regimen of chemotherapy
administration, patient-speciﬁc chemotherapy dosage, and
adverse eﬀects of treatment cannot be abstracted reliably
from the SEER-Medicare database. While reluctance of older
patients to receive chemotherapy due to perceived toxicities,
tolerability, or an apathetic attitude often are diﬃcult to
enumerate, physical limitations such as comorbid disease
may be more reliably estimated in a population-based
database that records these factors. In the current study, a
high Charlson comorbidity index was not associated with
more infrequent chemoradiation treatment. Comorbid renal
disease, as identiﬁed by diagnosis codes for renal disease,
renal failure, or renal insuﬃciency, also was not associated
with infrequent chemoradiation treatment.
Demographic variables of race, socioeconomic status,
and tumor variables of histology and clinical stage were not
associated with more infrequent chemoradiation treatment,
a reassuring ﬁnding of this study. However, a signiﬁcant dis-
parityintheproportionofwomen ≥55yearsinmetropolitan
and nonmetropolitan residencies was observed in this study.
Only 40 percent of the women residing in metropolitan areas
as compared to 60 percent of women residing in urban,
less urban, and rural residencies received chemoradiation
during the entire 1998 to 2002 period under study (P =
.03). Disparity in age cohorts among residences does not
account for this diﬀerence as the proportion of women aged
71 years or older among big metropolitan, metropolitan,
and urban/less urban/rural areas is similar (P = .41).
The issues surrounding the more frequent use of radiation
alone in metropolitan residencies are diﬃcult to abstract but
perhaps are related to unreported comorbid disease, patient
refusal, and perceived toxicities/tolerability of the combined
treatment regimen. The data cannot exclude the possibility
that healthcare-system-related factors, such as access to care
or diﬀerences in referrals for chemotherapy consultation,
could explain the ﬁndings of the current study. The reasons
why older women do not receive chemotherapy remain
elusive, and perhaps, future population-based studies may
provide more meaningful insight.
Our study is not without interpretative criticism. The
population covered by SEER program representing 26 per-
cent of the general population compares favorably to US
census population data with regard to measures of poverty
and education, but has a higher proportion of urban and
foreign-born persons in the registry as compared to the
general US population. Census population estimates for
the year 2000 [19] suggest that 73 percent of women aged
≥55 years live in metropolitan areas as compared to 85
percent registered in the SEER-Medicare dataset. There may
also be diﬀerences in the underlying racial distribution of
the SEER-Medicare dataset compared to the US population
comprising new incident cases of cervical cancer [20]. This
SEER-Medicare dataset used to analyze the impact of the
NCI clinical alert is limited to women aged ≥55 years that
must have been enrolled in Medicare Part A and B coverage
for the duration of their cervical cancer treatment. Thus,
by limiting the dataset by an age criterion of ≥55 years,
this analysis does not capture chemoradiation treatment in
young women who comprise the majority of new incident
cases in the US. Moreover, identiﬁcation of chemoradiation
in the SEER-Medicare population follows the Centers for
Medicare and Medicaid Services’ coverage policies relating
to chemotherapy administration. Current Centers for Medi-
care and Medicaid Services policy permits fee-for-service
reimbursement for intravenous chemotherapy [7], including
cisplatin chemotherapy administration. As Medicare billing
claims for chemotherapy administration are often coded
withinsixmonthsofinitialcancerdiagnosis[7],thisanalysis’
three-month timeframe for coincident chemotherapy and
radiation treatment in the SEER-Medicare dataset is reason-
able. Women simultaneously enrolled by a private insurer
were excluded as chemotherapy administration may have
been paid by this entity rather than Medicare, and thus
falselyskewingresultstowardtreatmentwithradiationalone.
Another limitation is that comorbid disease documentation
in a population-based dataset is derived from claims-based
administrative coding, which may generally be less com-
plete than data obtained from direct medical chart review.
Interpretative criticism also concerns the timeliness of the
SEER-Medicare cohort under study, as these patients may
be poorly reﬂective of modern chemoradiation practice; and
yet, SEER data and Medicare data are infrequently merged.
As such, the 1998–2002 SEER-Medicare patient population
represents the most contemporary cohort in which to study
concurrent SEER radiation and Medicare chemotherapy
recorded administration.
The current analysis of 1998–2002 SEER-Medicare data
indicates increased utilization of chemoradiation treatment
since the 1999 NCI clinical alert strongly advocating for
concurrent chemotherapy and radiation for locally advanced
cervical cancer. Older age has been considered a barrier
to chemotherapy. Between 1998 and 2002, the population-
based SEER-Medicare registry identiﬁes 43 percent of the
women ≥55 years with locally advanced cervical cancer
receiving chemoradiation despite published guidelines to the
contrary. While our study is provocative, it is unable to
deﬁnitively assess current national chemoradiation practice
patterns. To further corroborate our ﬁndings, it would be
interesting to analyze NCI-sponsored clinical trials enrolling
women aged ≥55 years to determine if the number of
chemotherapy cycles given during radiation impacts clinical
outcome. Further analysis of national practice patterns from
future US Surveillance, Epidemiology, and End-Results-
Medicare mergers is warranted to identify contributing
factors leading to the disparity in incidence and mortality
among women ≥55 years with locally advanced cervical
cancer.
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